Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Bcma binding molecules and methods of use thereof

An antigen binding molecule, B cell technology, applied in the field of treating cancer or other diseases or conditions in patients, which can solve problems such as adverse side effects

Active Publication Date: 2019-03-01
KITE PHARMA INC
View PDF31 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Current therapies for hematological malignancies have demonstrated varying degrees of effectiveness and have adverse side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bcma binding molecules and methods of use thereof
  • Bcma binding molecules and methods of use thereof
  • Bcma binding molecules and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0551] BCMA expression was measured in various cell lines. BCMA was found to be expressed (fragments / kilobase-long exons / million mapped reads (FPKM) greater than 35) in 99% of multiple myeloma tumor cell lines tested (Figure 2A). BCMA expression was higher than that of CD70, CS-1, CLL-1, DLL-1 and FLT3 (Fig. 2A). To further characterize the expression of BCMA, EoL-1 (Sigma) was stained with an anti-BCMA antibody conjugated to PE (Biolegend, San Diego, CA) in staining buffer (BD Pharmingen, San Jose, CA) at 4°C. , NCI-H929 (Molecular Imaging) and MM1S (Molecular Imaging) staining for 30 minutes. Cells were then washed and resuspended in staining buffer with propidium iodide (BD Pharmingen) prior to data acquisition. Then, samples were obtained by flow cytometry and data were analyzed ( Figures 2B to 2C ). In the myeloma cell line MM1S( Figure 2C ) and NCI-H929 ( Figure 2D ) but not in the human eosinophil cell line EoL-1 ( Figure 2B ). Furthermore, little to no BCMA...

Embodiment 2

[0553] A third-generation lentiviral transfer vector containing the BCMA CAR construct was combined with the ViraPower TM Lentiviral packaging mix (Life Technologies, FIX TM ) to generate the lentiviral supernatant. Briefly, a transfection mixture was generated by mixing 15 μg of DNA and 22.5 μl of polyethileneimine polyethileneimine (Polysciences, 1 mg / ml) in 600 μl of OptiMEM medium. The transfection mixture was incubated for 5 minutes at room temperature. At the same time, 293T cells (ATCC) were trypsinized and counted. Then, add up to 10x10 6 293T cells were plated together with the transfection mixture in a T75 flask. After three days of cultivation, the supernatant was collected and filtered through a 0.45 μm filter before being stored at −80°C.

[0554] Peripheral blood mononuclear cells (PBMCs) were isolated from leukocyte concentrates (leukopak) (Hemacare) from two different healthy donors using ficoll-paque gradient density centrifugation according to the manufa...

Embodiment 3

[0560] Antigens were biotinylated using the EZ-Link Sulfo-NHS-Biotinylation Kit from Pierce / ThermoFisher (Waltham, MA). Goat anti-human F(ab')2κ-FITC (LC-FITC), Extravidin-PE ( EA-PE) and streptavidin 633 (SA-633). Streptavidin microbeads and MACS LC separation columns were purchased from Miltenyi Biotec (Gladbachn, Germany).

[0561] initial discovery

[0562]Eight initial human synthetic yeast pools each with a diversity of approximately 109 were propagated as described herein (see WO2009036379, WO2010105256 and WO2012009568 by Xu et al.). For the first two selection rounds, the Miltenyi MACs system was used for magnetic bead sorting as described ((Siegel et al., 2004). Briefly, yeast cells (approximately 1010 cells / pool) were mixed with 3 ml of 100 nM Biotinylated monomeric antigen or 10 nM biotinylated Fc fusion antigen was incubated for 15 minutes at room temperature in FACS wash buffer (phosphate-buffered saline (PBS) / 0.1% bovine serum albumin (BSA)). Use 50 ml Aft...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 317,334, filed April 1, 2016, which is hereby incorporated by reference in its entirety. [0003] sequence listing [0004] This application contains a Sequence Listing that has been electronically filed in ASCII format and is hereby incorporated by reference in its entirety. The ASCII copy created on March 30, 2017 is called K-1030_02_SL.txt and is 387,353 bytes in size. field of invention [0005] The present invention relates to chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising antigen-binding molecules that bind to B-cell maturation antigen (BCMA), polynucleotides encoding the same, and their use to treat cancer or Methods for Other Diseases or Conditions. Background of the invention [0006] Human cancers essentially consist of normal cells that undergo genetic or epigenetic transformation to beco...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/12A61K38/17A61K39/395C07K14/705C07K16/30
CPCC07K16/2878C07K14/7051C07K2317/565C07K2317/56C07K2317/622C07K2317/92A61K31/675A61K31/7076A61K31/7088A61K45/06C07K14/70521A61K35/00C07K2319/03C07K2319/33C07K2319/30C07K2317/53A61P35/00A61P35/02A61K2300/00C07K14/70575C07K14/70596C12N5/0636C07K2319/02C12N2510/00
Inventor J.维尔特齐乌斯R.阿尔瓦雷茨罗德里格兹
Owner KITE PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com